Modotuximab
- Generic Name
- Modotuximab
- Drug Type
- Biotech
- CAS Number
- 1310460-86-6
- Unique Ingredient Identifier
- 1W7BD1M08N
- Background
Modotuximab is under investigation in clinical trial NCT03549338 (Sym004 Versus Futuximab or Modotuximab in Patients With mCRC).
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Phase 2
Terminated
- Conditions
- Colorectal Cancer MetastaticMetastatic Colorectal CancerCarcinoma
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 2
- Registration Number
- NCT03549338
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇪🇸Hospital Clínico de Valencia, Valencia, Spain
🇩🇪Asklepios Kliniken Altona, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath